Literature DB >> 8832983

Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis.

J M Kremer1, D E Furst, M E Weinblatt, S D Blotner.   

Abstract

OBJECTIVE: To describe the statistical association between serum AST and liver biopsy grade in patients with rheumatoid arthritis.
METHODS: 94 patients from 3 prospectively followed cohorts underwent a total of 354 biopsies graded according to Roenigk. Blood samples for serum aminotransferase (AST) were obtained every 37.7 + or - 32.7 days (mean + or - SD) and 15.2 + or - 7.1 samples were obtained before each biopsy. For each prebiopsy interval, 4 AST functions were calculated: (1) mean, (2) maximum, (3) percentage abnormal, and (4) the presence or absence of at least one abnormality. Analysis of variance was performed to determine the effect of each of these variables on liver biopsy score.
RESULTS: AST increased across biopsy grades: 26.5 IU + or - 10.7 IU (mean + or - SD) in Grade I biopsies, 28.4 + or - 10.9 in Grade II, and 35.4 + or - 21.1 in Grade IIIA (p = 0.0006, overall difference between classes). The percentage of abnormal prebiopsy AST values increased across biopsy grades: 8.7 + or - 13.9 (mean + or - SD) in Grade I biopsies, 12.3 + or - 17.5 in Grade II, and 18.6 + or - 27.1 in Grade IIIA samples [(p = 0.0014) overall difference between classes.] A mean prebiopsy AST in the abnormal range was more likely to be associated with a more abnormal liver biopsy grade (p = 0.01, Wilcoxon's rank sum test). AST values abnormal <49% of the time had a 97% specificity for a normal biopsy grade.
CONCLUSION: Regular AST measurements are useful markers of hepatic histologic outcome, within the range of mostly normal histology reported here, in patients with RA receiving longterm weekly MTX.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8832983

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Automatic identification of methotrexate-induced liver toxicity in patients with rheumatoid arthritis from the electronic medical record.

Authors:  Chen Lin; Elizabeth W Karlson; Dmitriy Dligach; Monica P Ramirez; Timothy A Miller; Huan Mo; Natalie S Braggs; Andrew Cagan; Vivian Gainer; Joshua C Denny; Guergana K Savova
Journal:  J Am Med Inform Assoc       Date:  2014-10-25       Impact factor: 4.497

2.  Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.

Authors:  J R Curtis; T Beukelman; A Onofrei; S Cassell; J D Greenberg; A Kavanaugh; G Reed; V Strand; J M Kremer
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

3.  Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment.

Authors:  Deana D Hoganson; Jun Chen; Richard L Ehman; Jayant A Talwalkar; Clement J Michet; Meng Yin; Cynthia S Crowson; Eric L Matteson
Journal:  Open J Rheumatol Autoimmune Dis       Date:  2012-05

4.  Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.

Authors:  Gabriela Schmajuk; Yinghui Miao; Jinoos Yazdany; W John Boscardin; David I Daikh; Michael A Steinman
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-08       Impact factor: 4.794

Review 5.  Management of drug-induced liver disease.

Authors:  G Marino; H J Zimmerman; J H Lewis
Journal:  Curr Gastroenterol Rep       Date:  2001-02

6.  Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.

Authors:  Jenny H Humphreys; Alexander Warner; Ruth Costello; Mark Lunt; Suzanne M M Verstappen; William G Dixon
Journal:  Ann Rheum Dis       Date:  2017-03-23       Impact factor: 19.103

7.  Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy.

Authors:  Yoon-Kyoung Sung; Soo-Kyung Cho; Dam Kim; Soyoung Won; Chan-Bum Choi; Tae-Hwan Kim; Jae-Bum Jun; Dae-Hyun Yoo; Sang-Cheol Bae
Journal:  Korean J Intern Med       Date:  2017-03-13       Impact factor: 2.884

Review 8.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

9.  Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Authors:  K Visser; W Katchamart; E Loza; J A Martinez-Lopez; C Salliot; J Trudeau; C Bombardier; L Carmona; D van der Heijde; J W J Bijlsma; D T Boumpas; H Canhao; C J Edwards; V Hamuryudan; T K Kvien; B F Leeb; E M Martín-Mola; H Mielants; U Müller-Ladner; G Murphy; M Østergaard; I A Pereira; C Ramos-Remus; G Valentini; J Zochling; M Dougados
Journal:  Ann Rheum Dis       Date:  2008-11-25       Impact factor: 19.103

10.  Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice.

Authors:  David J Shealy; Paul H Wooley; Eva Emmell; Amy Volk; Amy Rosenberg; George Treacy; Carrie L Wagner; Lois Mayton; Don E Griswold; Xiao-Yu R Song
Journal:  Arthritis Res       Date:  2002-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.